Advancements in the Diagnosis and Therapeutics for Non-Small Cell Lung Carcinoma (NSCLC): From Genetic Mutations to Public Health Perspectives

Lung cancer, particularly non-small cell lung carcinoma (NSCLC), poses significant challenges in oncology. Accounting for approximately 85% of lung cancerrelated deaths, NSCLC's aggressive nature demands comprehensive management
strategies. Environmental factors like smoking and air pollution, alongside genetic
mutations in genes such as EGFR, KRAS, and ALK, contribute to its development.
Recent advancements in diagnostic modalities, including low-dose CT scans and
molecular profiling, facilitate early detection. Treatment paradigms have evolved to
incorporate multimodal approaches, encompassing surgery, radiotherapy, chemotherapy, targeted therapies, and immunotherapy. Collaboration among healthcare
professionals is crucial for effective patient care. As research continues to unfold,
novel therapeutic strategies and personalized medicine approaches hold promise
for improving outcomes in NSCLC patients.